These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28487698)

  • 21. The Rules of Human T Cell Fate
    Costa Del Amo P; Debebe B; Razavi-Mohseni M; Nakaoka S; Worth A; Wallace D; Beverley P; Macallan D; Asquith B
    Front Immunol; 2020; 11():573. PubMed ID: 32322253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerated in vivo proliferation of memory phenotype CD4+ T-cells in human HIV-1 infection irrespective of viral chemokine co-receptor tropism.
    Zhang Y; de Lara C; Worth A; Hegedus A; Laamanen K; Beverley P; Macallan D
    PLoS Pathog; 2013; 9(4):e1003310. PubMed ID: 23637601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mass spectrometry-based microassay of (2)H and (13)C plasma glucose labeling to quantify liver metabolic fluxes in vivo.
    Hasenour CM; Wall ML; Ridley DE; Hughey CC; James FD; Wasserman DH; Young JD
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E191-203. PubMed ID: 25991647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of ribosomal RNA turnover in vivo by use of deuterium-labeled glucose.
    Defoiche J; Zhang Y; Lagneaux L; Pettengell R; Hegedus A; Willems L; Macallan DC
    Clin Chem; 2009 Oct; 55(10):1824-33. PubMed ID: 19696118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parameters for pyrethroid insecticide QSAR and PBPK/PD models for human risk assessment.
    Knaak JB; Dary CC; Zhang X; Gerlach RW; Tornero-Velez R; Chang DT; Goldsmith R; Blancato JN
    Rev Environ Contam Toxicol; 2012; 219():1-114. PubMed ID: 22610175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a physiologically based pharmacokinetic model for assessment of human exposure to bisphenol A.
    Yang X; Doerge DR; Teeguarden JG; Fisher JW
    Toxicol Appl Pharmacol; 2015 Dec; 289(3):442-56. PubMed ID: 26522835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantifying the contribution of gluconeogenesis to glucose production in fasted human subjects using stable isotopes.
    Landau BR
    Proc Nutr Soc; 1999 Nov; 58(4):963-72. PubMed ID: 10817164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologically based pharmacokinetic modeling of POPs in Greenlanders.
    Sonne C; Gustavson K; Rigét FF; Dietz R; Krüger T; Bonefeld-Jørgensen EC
    Environ Int; 2014 Mar; 64():91-7. PubMed ID: 24382481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current best estimates for the average lifespans of mouse and human leukocytes: reviewing two decades of deuterium-labeling experiments.
    Borghans JAM; Tesselaar K; de Boer RJ
    Immunol Rev; 2018 Sep; 285(1):233-248. PubMed ID: 30129193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a human physiologically based pharmacokinetic (PBPK) model for phthalate (DEHP) and its metabolites: A bottom up modeling approach.
    Sharma RP; Schuhmacher M; Kumar V
    Toxicol Lett; 2018 Oct; 296():152-162. PubMed ID: 29958929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans.
    Tardif R; Charest-Tardif G; Brodeur J; Krishnan K
    Toxicol Appl Pharmacol; 1997 May; 144(1):120-34. PubMed ID: 9169076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA-protein cross-links (DPX) and cell proliferation in B6C3F1 mice but not Syrian golden hamsters exposed to dichloromethane: pharmacokinetics and risk assessment with DPX as dosimeter.
    Casanova M; Conolly RB; Heck H d'A
    Fundam Appl Toxicol; 1996 May; 31(1):103-16. PubMed ID: 8998946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
    Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
    AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantifying the contribution of dietary protein to whole body protein kinetics: examination of the intrinsically labeled proteins method.
    Wolfe RR; Park S; Kim IY; Starck C; Marquis BJ; Ferrando AA; Moughan PJ
    Am J Physiol Endocrinol Metab; 2019 Jul; 317(1):E74-E84. PubMed ID: 30939051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation.
    Ellison CA
    Regul Toxicol Pharmacol; 2018 Nov; 99():61-77. PubMed ID: 30201539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.
    Bollyky JB; Long SA; Fitch M; Bollyky PL; Rieck M; Rogers R; Samuels PL; Sanda S; Buckner JH; Hellerstein MK; Greenbaum CJ
    Clin Exp Immunol; 2013 Jun; 172(3):363-74. PubMed ID: 23600824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.